Defining optimal treatment strategies for nasopharyngeal carcinoma based on the ninth edition TNM staging system: insights from a multicenter cohort study in an endemic region
The ninth edition AJCC/UICC staging system (TNM-9) for nasopharyngeal carcinoma (NPC) was released in 2025, prompting a need to redefine evidence‐based treatment regimens.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Efficacy and Toxicity of Triweekly Versus Weekly Cisplatin in Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma